Full Text Journal Articles by
Author Mary V Jacoski

Advertisement

Find full text journal articles








Advances in subcutaneous injections: PRECISE II: a study of safety and subject preference for an innovative needle-free injection system.

E Lynne Kelley, Richard H Smith, Gillian Corcoran, Sandra Nygren, Mary V Jacoski, Andrea Fernandes,

Needle-free injection is a desirable goal for many reasons, including reducing pain, anxiety, and eliminating safety risks associated with needle-stick injuries. However, development of a safe, reliable needle-free device optimized for at-home use has been met with many challenges. Portal Instruments Inc. has been developing needle-free medication delivery using a ... Read more >>

Drug Deliv (Drug delivery)
[2021, 28(1):1915-1922]

Cited: 0 times

View full text PDF listing >>



Machine Learning Approaches to Analyzing Adverse Events Following Durable LVAD Implantation.

Arman Kilic, Jana Macickova, Lingli Duan, Faezeh Movahedi, Laura Seese, Yiye Zhang, Mary V Jacoski, Rema Padman,

<h4>Background</h4>This study employed machine learning approaches to analyze sequences of adverse events (AEs) after left ventricular assist device (LVAD) implantation.<h4>Methods</h4>Data on patients implanted with the HeartWare HVAD durable LVAD were extracted from the ENDURANCE and ENDURANCE Supplemental clinical trials, with follow-up through 5 years. Major AEs included device malfunction, major ... Read more >>

Ann Thorac Surg (The Annals of thoracic surgery)
[2021, 112(3):770-777]

Cited: 0 times

View full text PDF listing >>



Advertisement

Interpreting Neurologic Outcomes in a Changing Trial Design Landscape: An Analysis of HeartWare Left Ventricular Assist Device Using a Hybrid Intention to Treat Population.

Claudius Mahr, Duc Thinh Pham, Nahush A Mokadam, Scott C Silvestry, Jennifer Cowger, Michael S Kiernan, David A D'alessandro, Erin E Coglianese, Muhammad Faraz Masood, Robert L Kormos, Mary V Jacoski, Jeffrey J Teuteberg,

Randomized controlled trials can provide optimal clinical evidence to assess the benefits of new devices, and it is these data that often shape device usage in real-world practice. However, individual clinical trial results sometimes appear discordant for the same device, and alternative devices are sometimes not employed in similar patient ... Read more >>

ASAIO J (ASAIO journal (American Society for Artificial Internal Organs : 1992))
[2019, 65(3):293-296]

Cited: 1 time

View full text PDF listing >>



An examination of survival by sex and race in the HeartWare Ventricular Assist Device for the Treatment of Advanced Heart Failure (ADVANCE) Bridge to Transplant (BTT) and continued access protocol trials.

Emma J Birks, Edwin C McGee, Keith D Aaronson, Steven Boyce, William G Cotts, Samer S Najjar, Francis D Pagani, David R Hathaway, Kevin Najarian, Mary V Jacoski, Mark S Slaughter, ,

<h4>Background</h4>The Ventricular Assist Device for the Treatment of Advanced Heart Failure (ADVANCE) Bridge to Transplant (BTT) trial was a multicenter, prospective trial of the HeartWare Ventricular Assist Device (HVAD). The performance of the HVAD in various demographic sub-groups was evaluated.<h4>Methods</h4>Baseline characteristics, adverse events, and survival were compared for men vs. ... Read more >>

J Heart Lung Transplant (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
[2015, 34(6):815-824]

Cited: 15 times

View full text PDF listing >>



Clinical outcomes after implantation of a centrifugal flow left ventricular assist device and concurrent cardiac valve procedures.

Carmelo Milano, Francis D Pagani, Mark S Slaughter, Duc Thinh Pham, David R Hathaway, Mary V Jacoski, Kevin B Najarian, Keith D Aaronson, ,

<h4>Background</h4>Cardiac valve procedures are commonly performed concurrently during implantation of left ventricular assist devices, but the added procedural risk has not been studied in detail.<h4>Methods and results</h4>Data from patients receiving the HeartWare Ventricular Assist Device in the ADVANCE bridge to transplant (BTT) trial and continued access protocol were reviewed. Of ... Read more >>

Circulation (Circulation)
[2014, 130(11 Suppl 1):S3-11]

Cited: 15 times

View full text PDF listing >>



Pharmacodynamic effects of clopidogrel in pediatric cardiac patients: a comparative study of platelet aggregation response.

Lisa K Jennings, Alan D Michelson, Mary V Jacoski, Aditya Tyagi, Svetozar Grgurevich, Jennifer S Li, Picolo Investigators,

Little data on pediatric percent platelet aggregation (%PA) exist in the literature, particularly in cardiac patients and in response to clopidogrel. The objectives were to estimate the %PA range expected in pediatric patients and to measure the clopidogrel effect on %PA in the PICOLO (Platelet Inhibition in Children on Clopidogrel) ... Read more >>

Platelets (Platelets)
[2012, 23(6):430-438]

Cited: 4 times

View full text PDF listing >>



Cardiovascular devices and platelet interactions: understanding the role of injury, flow, and cellular responses.

Jesse W Rowley, Aloke V Finn, Patricia A French, Lisa K Jennings, Danny Bluestein, Peter L Gross, Jane E Freedman, Steven R Steinhubl, Guy A Zimmerman, Richard C Becker, Harold L Dauerman, Susan S Smyth, ,

Circ Cardiovasc Interv (Circulation. Cardiovascular interventions)
[2012, 5(2):296-304]

Cited: 5 times

View full text PDF listing >>



A clinical risk score for the prediction of very late stent thrombosis in drug eluting stent patients.

Kenneth W Baran, John M Lasala, David A Cox, Stephen R Mascioli, Aijun Song, Mahesh C Deshpande, Mary V Jacoski, Keith D Dawkins, ,

<h4>Aims</h4>Very late stent thrombosis (VLST; >1 year) is an infrequent but potentially serious complication, whose risk factors have not been fully elucidated. This investigation sought to develop a clinically useful risk stratification score for VLST following drug eluting stent (DES) placement.<h4>Methods and results</h4>A Cox proportional hazards multivariate model of VLST ... Read more >>

EuroIntervention (EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology)
[2011, 6(8):949-954]

Cited: 9 times

View full text PDF listing >>



A clinical risk score for prediction of stent thrombosis.

Kenneth W Baran, John M Lasala, David A Cox, Aijun Song, Mahesh C Deshpande, Mary V Jacoski, Stephen R Mascioli, ,

The aim was to develop a clinically useful patient risk score predictive for stent thrombosis (ST). Using readily available baseline clinical and angiographic characteristics, a Cox proportional hazards multivariate model was used to identify significant (p <0.10) predictors of ST through 1 year in 2,487 patients receiving a TAXUS Express ... Read more >>

Am J Cardiol (The American journal of cardiology)
[2008, 102(5):541-545]

Cited: 19 times

View full text PDF listing >>



The use of the point of care Helena ICHOR/Plateletworks and the Accumetrics Ultegra RPFA for assessment of platelet function with GPIIB-IIIa antagonists.

Melanie M White, Rajini Krishnan, Teddi J Kueter, Mary V Jacoski, Lisa K Jennings,

<h4>Objective</h4>To evaluate a newly modified rapid platelet function analysis system (ICHOR/ Plateletworks) and to compare the results obtained with those of traditional light transmission aggregometry (LTA), and the Ultegra/RPFA system.<h4>Background</h4>Anti-platelet therapy is standard of care for patients as an adjunct to percutaneous coronary intervention (PCI) or for medical management of ... Read more >>

J Thromb Thrombolysis (Journal of thrombosis and thrombolysis)
[2004, 18(3):163-169]

Cited: 16 times

View full text PDF listing >>



Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study).

Jorge F Saucedo, Luis Garza, David C Wolford, Stephen L Cook, Kodangudi B Ramanathan, Zakaria Matin, Frank A McGrew, Mary V Jacoski, Lisa K Jennings, ,

We performed a comparative analysis of platelet aggregation inhibition achieved with the glycoprotein IIb/IIIa inhibitors eptifibatide and tirofiban HCl in patients who underwent percutaneous coronary intervention and used light transmission aggregometric assays with D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone as an anticoagulant and 20 micromol of adenosine diphosphate as an agonist. Taking into ... Read more >>

Am J Cardiol (The American journal of cardiology)
[2004, 93(10):1279-1282]

Cited: 6 times

View full text PDF listing >>



Comparative pharmacodynamic evaluation of eptifibatide and abciximab in patients with non-ST-segment elevation acute coronary syndromes: the TAM2 study.

Jorge F Saucedo, Henry K Lui, Luis Garza, G Jose Guerra, Mary V Jacoski, Lisa K Jennings,

<h4>Background</h4>The importance of the relationship between clinical outcome and degree of platelet aggregation inhibition (PAI) achieved with the dosing regimens of GPIIb-IIIa inhibitors used in large trials in patients with non-ST segment elevation (NSTE) acute coronary syndromes (ACS) is increasingly appreciated. In the PURSUIT trial, eptifibatide treatment that consistently provided ... Read more >>

J Thromb Thrombolysis (Journal of thrombosis and thrombolysis)
[2004, 18(2):67-74]

Cited: 9 times

View full text PDF listing >>



The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors.

Lisa K Jennings, Mary V Jacoski, Melanie McCabe White,

Glycoprotein (GP) IIb/IIIa antagonists are a unique class of antiplatelet agents introduced for the management of patients undergoing percutaneous coronary intervention (PCI) and those presenting with unstable angina or non-ST segment elevation (NSTE) myocardial infarction (MI), collectively recognized as acute coronary syndromes (ACS). Eptifibatide, abciximab, and tirofiban HCl are three ... Read more >>

J Interv Cardiol (Journal of interventional cardiology)
[2002, 15(1):45-60]

Cited: 18 times

View full text PDF listing >>





Advertisement


Disclaimer

0.8323 s